Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: A systematic review of methodological papers by Alshreef, A. et al.
This is a repository copy of Statistical methods for adjusting estimates of treatment 
effectiveness for patient nonadherence in the context of time-to-event outcomes and 
health technology assessment: A systematic review of methodological papers.




Alshreef, A. orcid.org/0000-0003-2737-1365, Latimer, N. orcid.org/0000-0001-5304-5585, 
Tappenden, P. et al. (4 more authors) (2019) Statistical methods for adjusting estimates of 
treatment effectiveness for patient nonadherence in the context of time-to-event outcomes 
and health technology assessment: A systematic review of methodological papers. Medical





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Review
Medical Decision Making
2019, Vol. 39(8) 910–925





Statistical Methods for Adjusting
Estimates of Treatment Effectiveness
for Patient Nonadherence in the Context
of Time-to-Event Outcomes and Health
Technology Assessment: A Systematic
Review of Methodological Papers
Abualbishr Alshreef , Nicholas Latimer, Paul Tappenden,
Ruth Wong, Dyfrig Hughes , James Fotheringham, and Simon Dixon
Introduction. Medication nonadherence can have a significant negative impact on treatment effectiveness. Standard
intention-to-treat analyses conducted alongside clinical trials do not make adjustments for nonadherence. Several
methods have been developed that attempt to estimate what treatment effectiveness would have been in the absence
of nonadherence. However, health technology assessment (HTA) needs to consider effectiveness under real-world
conditions, where nonadherence levels typically differ from those observed in trials. With this analytical requirement
in mind, we conducted a review to identify methods for adjusting estimates of treatment effectiveness in the presence
of patient nonadherence to assess their suitability for use in HTA. Methods. A ‘‘Comprehensive Pearl Growing’’ tech-
nique, with citation searching and reference checking, was applied across 7 electronic databases to identify methodo-
logical papers for adjusting time-to-event outcomes for nonadherence using individual patient data. A narrative
synthesis of identified methods was conducted. Methods were assessed in terms of their ability to reestimate effective-
ness based on alternative, suboptimal adherence levels. Results. Twenty relevant methodological papers covering 12
methods and 8 extensions to those methods were identified. Methods are broadly classified into 4 groups: 1) simple
methods, 2) principal stratification methods, 3) generalized methods (g-methods), and 4) pharmacometrics-based
methods using pharmacokinetics and pharmacodynamics (PKPD) analysis. Each method makes specific assumptions
and has associated limitations. Five of the 12 methods are capable of adjusting for real-world nonadherence, with
only g-methods and PKPD considered appropriate for HTA. Conclusion. A range of statistical methods is available
for adjusting estimates of treatment effectiveness for nonadherence, but most are not suitable for use in HTA. G-
methods and PKPD appear to be more appropriate to estimate effectiveness in the presence of real-world adherence.
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Patient nonadherence to medications can have a signifi-
cant negative impact on treatment effectiveness and
health care costs and has the potential to alter the con-
clusions of economic evaluations and health technology
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assessments (HTAs).1–3 An economic evaluation typically
assesses the cost-effectiveness of a new treatment com-
pared to standard treatment using evidence on clinical
effectiveness and costs. Intention-to-treat (ITT) analysis,
which compares randomized groups regardless of nonad-
herence or withdrawal, is a well-established method for
estimating treatment effectiveness from randomized con-
trolled trials (RCTs).4 However, ITT estimates may not
be relevant if the HTA aims to assess the effectiveness of
treatment given real-world adherence patterns.5,6
There is evidence to show that adherence in the real
world is likely to differ from RCTs (depending on the
type of treatment, disease area, and health care setting),
which leads to uncertainty around the actual effectiveness
of treatments.7–9 Clinical effectiveness estimates have a
direct impact on cost-effectiveness; consequently, a cost-
effectiveness analysis (CEA) that does not incorporate
nonadherence may produce misleading conclusions
regarding the value of the technology. In the HTA con-
text, we are interested in effectiveness estimates inferred
to the entire study population (as defined by scope and
study eligibility criteria), which can be identified at base-
line, as opposed to estimates focused on a latent sub-
group of the population (e.g., compliers). Moreover,
HTA agencies are interested in adjustment methods,
which can be used for reestimating treatment effective-
ness for any given level of adherence, to reflect potential
real-world adherence levels.10,11
The fundamental issue in estimating effectiveness asso-
ciated with alternative adherence levels is the methodologi-
cal challenge associated with adjusting for time-dependent
confounding. In this context, time-dependent confounders
are prognostic factors that predict subsequent nonadher-
ence and outcomes, yet are themselves predicted by previ-
ous nonadherence.12 When time-dependent confounders
are present, more complex methods than simple regression
adjustment are needed because simple regression adjust-
ment is unable to deal with variables that predict adher-
ence and are also an intermediate step between adherence
and outcome. A range of methods has been proposed for
estimating the causal effect of treatments in the presence
of nonadherence, but little guidance exists about their rela-
tive advantages,13–15 and not all deal with time-dependent
confounding appropriately. In addition, these methods
have been designed, principally, to reestimate effectiveness
assuming perfect adherence, whereas HTA requires reesti-
mation for suboptimal (real-world) adherence.
The aims of the review are to systematically identify
approaches for adjusting for nonadherence in the context
of time-to-event outcomes using individual patient data
in RCTs, to describe how each is undertaken, and to
assess their suitability for reestimating effectiveness based
on alternative, suboptimal adherence levels.
Methods
Review Question and Protocol
The review question was as follows: ‘‘What methods have
been proposed in the methodological literature to
account for the impact of nonadherence to treatments on
clinical effectiveness and cost-effectiveness?’’ The review
approach adheres to published international guidelines
for undertaking and reporting systematic reviews, and
methods were prespecified in a protocol.16–20
Search Strategy
A ‘‘Comprehensive Pearl Growing’’ (CPG) technique17
and 2-stage iterative search approach was used across 7
databases (MEDLINE, Embase, Cochrane Library,
EconLit, Scopus, Web of Science, MathSciNet).
Databases were searched for potentially relevant papers
published in English from inception to February 9, 2018
(first stage search), to May 23, 2018 (second stage
search). The database searches were complemented by
citation searches and reference list checking for each
‘‘pearl’’ (key paper) to identify additional relevant papers.
The search approach was designed to identify the initial
paper proposing the method (or articles reporting exten-
sions to a previously developed method), rather than arti-
cles reporting the application of methods in studies.
The database search strategy comprises keywords for
patient adherence combined with methods terms and
focused MeSH headings of known pearls. The second
stage search was informed from the collective analysis of
newly identified pearls title, abstract, keywords, and
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MeSH and floating headings using the online Yale
MeSH Analyzer Tool.13,21–28 Search terms and strategies
are provided in online Supplementary Appendix A.
Inclusion and Exclusion Criteria
The selection of papers included for narrative synthesis
was conducted in 2 stages: 1) records retrieved from all
sources were screened by titles followed by abstracts
screening, and 2) potentially relevant full-text articles were
assessed for eligibility using the inclusion and exclusion cri-
teria (Suppl. Table S1 in Appendix B). One author (AA)
screened all potentially relevant papers retrieved. A second
author (SD) independently screened a subset of papers
against the eligibility criteria. Disagreements between the 2
reviewers were resolved by discussion, and a consensus
was reached on the final list of included papers. Expert
opinion was obtained from 2 experts (DH, IW) for recom-
mendation of additional papers.
Data Extraction
A data extraction form was developed to extract the
basic information and key characteristics for each
method identified (Suppl. Table S2 in Appendix B).
Data Synthesis
A narrative data synthesis approach was followed for
each relevant method identified and its extensions. This
included a description of the key characteristics of each
method, as specified by the appraisal framework
(Suppl. Table S3 in Appendix B).29 As part of this, we
assessed which forms of nonadherence the method is
capable of addressing, using the classification devel-
oped by Vrijens and colleagues.28 This classification
differentiates between 3 stages of medication nonad-
herence: 1) initiation (when the first dose is taken by
the patient), 2) implementation (how closely the actual
dosage of a patient corresponds to the prescribed dos-
ing regimen), and 3) persistence (time to discontinua-
tion or end of therapy).28
We provide a brief description of the concept of each
adjustment method, together with the causal model, its
estimand (defined in the next section), key assumptions,
and limitations. We assess whether the method is capable
of reestimating effectiveness for other suboptimal levels
of adherence (as opposed to optimal adherence). This
assessment was based on the capability of the method to
estimate the treatment effect under alternative counter-
factual adherence levels (i.e., not observed adherence lev-
els) given the adherence level and treatment effect
actually observed in the trial. Finally, we assess the
appropriateness of nonadherence adjustment methods
for the HTA context based on criteria developed by the
authors. The criteria were 1) the suitability of the esti-
mand (as described in the next section), 2) the types of
nonadherence the method is capable of dealing with, and
3) whether it is possible to use the method to account for
real-world nonadherence levels.
Possible Estimands and Suitability for HTA
An estimand is the parameter of interest estimated by
the statistical method that we can use to make inferences
about a population using a sample from that popula-
tion.5,30 A range of possible estimands was identified,
but only a few are appropriate for HTA. In the HTA
context, resource allocation decisions are usually made
for a specified population defined by the scope for each
decision problem. Hence, the estimands of interest are
those covering the entire study population (as specified
by the RCT eligibility criteria), and this should be identi-
fiable at baseline for resource allocation decision mak-
ing. Therefore, estimands focused on latent subgroups of
patients (e.g., compliers) may not be appropriate for the
HTA context.
Results
Overview of Included Papers
This review includes 20 papers describing 12 methods
and 8 extensions to those methods.22,31–49 In total, the
searches resulted in 4472 records (Figure 1). The included
papers were published between 1992 and 2018 (inclusive);
the majority were published in the Statistics in Medicine
journal (30%) and Biometrics journal (25%). Other char-
acteristics of included papers are given in Supplementary
Table S4 in Appendix B.
Taxonomy of Methods
A taxonomy of methods for adjusting estimates of treat-
ment effectiveness for nonadherence in the context of
time-to-event outcomes is proposed (Table 1). The pur-
pose of the taxonomy is to increase understanding of the
concept behind each method and its relation to other
methods in terms of estimands and estimators.30 The
structure of the taxonomy was initially developed by 1
author (AA) and further revised based on consultations
with other authors (NL, PT, DH, JF, SD) and an expert
in causal inference methods (IW).
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Records idenfied through 
database searching 
(n =  1520 + 1757)
Duplicates removed 
(n = 373 + 764)
Records screened 
(n =  1156 + 993)
Records excluded 
(n = 1079 + 960)
By tle (n=1048 + 917)
By abstract (n=31 + 43)
Records via citaon searches 
and references lists
(n = 895 + 291)
Records excluded 
(n = 870 + 281)
By tle (n=848 + 271)
By abstract (n=22 + 10)
Addional records idenfied 
through other sources 
(n =  9)
Full-text articles excluded, with reasons 
(n= 70 + 32):
− Continuous outcomes (n=17 + 10)
− Binary outcomes (n=16 + 5)
− Categorical outcomes (n=5 + 1)
− No patient outcome (n=7 + 5)
− Pharmacokinetics and 
Pharmacodynamics only (n= 9 + 1)
− Economic evaluations (n= 9 + 2)
− Application of known method 
without extension (n=9 + 8)
− Not a methodological paper (n=1 +2)
− Not met definition of non-adherence
(n= 3)
− Assessed associations (n= 1)
− Theoretical paper (n=1)
− Comparisons of known methods 
(n=6 + 2)
Full-text arcles assessed 
for eligibility 
(n = 77 + 33)
Papers included in qualitave synthesis 
(n = 20)
Full-text arcles assessed 
for eligibility 
(n =  25 + 10)
Full-text articles excluded, with 
reasons (n= 19 + 9):
− Continuous outcomes (n= 8 + 1)
− Binary outcomes (n= 9 + 1)
− Categorical outcomes (n= 2)
− No patient outcome (n=3 + 1)
− Pharmacokinetics and
Pharmacodynamics only (n= 3)
− Economic evaluation (n=1)
− Application of known method 
without extension (n=7 + 3)
− Not a methodological paper (n=3)
− Not peer-reviewed (n=2 +1)
− Not met definition of non-
adherence (n=2)
− Assessed associations (n= 1)
− Theoretical paper (n=1)
− Comparisons of known methods 
(n=3 +1)
Papers included 
(n = 7+ 1)
Papers suggested by experts 
(n = 4)
Papers included 






























Figure 1 PRISMA Flow Diagram. PRISMA, preferred reporting items for systematic reviews and meta-analyses. Numbers in
red represent records from the 2nd stage of searches. The dashed lines show that citation searches and references lists checking
were done for pearls identified from databases searching. Papers excluded for the reason of ‘‘comparison of known methods’’ are
included in the citation searches and references lists checking as these were considered relevant for this purpose.
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In the proposed taxonomy, methods are broadly
classed into 4 groups: 1) simple methods that do not
appropriately adjust for nonadherence; 2) principal stra-
tification methods for estimating the complier average
causal effect (CACE) estimand50; 3) generalized methods
(g-methods), which are based on the counterfactual out-
come framework originally developed by Neyman51 and
Rubin52 for estimating the effect of time-fixed treat-
ments, as well as further extended by Robins et al.53,54
for time-varying treatments; and 4) pharmacometric-
based methods as a unique approach using pharmacoki-
netics and pharmacodynamics (PKPD) analysis com-
monly used in clinical trials for evaluating newly
developed pharmacological interventions. The estimand





Simple methods ITTa Intention-to-treat (ITT) analysis Yu et al., 201546
PP Per-protocol (PP) analysis Wu et al., 201545




CPH with PLE Cox proportional hazards (CPH) model with
partial likelihood estimator (PLE)
Cuzick et al., 200741
MCC Markov compliance class (MCC) model in a 3-
stage method (3SM)
Lin et al., 200742
Wtd PP Weighted per-protocol (Wtd PP) analysis using a
proportional hazards model with an
expectation-maximization (EM) estimator
Li and Gray, 201647




IV Instrumental variable (IV) with likelihood
estimator
Baker, 199832
IV extension: IV with plug-in nonparametric
empirical maximum likelihood estimation
(PNEMLE)
Nie et al., 201143
IV extension: transformation promotion time
cure model with maximum likelihood
estimation to estimate the complier average
causal effect (CACE) and the complier effect on
survival probability (CESP)
Gao and Zheng, 201748
G-methods MSMs Marginal structural models (MSMs) with inverse
probability of censoring weighting (IPCW)
Robins and Finkelstein,
200022
MSM extension: MSMs with inverse probability
of treatment weighting (IPTW)
Hernan et al., 200135
SNFTMs Structural nested failure time models (SNFTMs)
with G-estimation
Robins et al., 199231
RPSFTMs Rank-preserving structural failure time models
(RPSFTMs) with G-estimation
Loeys et al., 200136
RPSFTM extension: incorporating covariates to
improve the precision of estimators
Korhonen and
Palmgren, 200237




RPSFTM extension: allowing for dependent
censoring
Matsui, 200440






PKPD Pharmacokinetics and pharmacodynamics
(PKPD)–based method
Pink et al., 201444
PKPD extension: modeling varying




aITT does not adjust for nonadherence but is included in the taxonomy as a ‘‘do nothing’’ approach (i.e., ignoring nonadherence).
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and key assumptions used by each method are provided
in Table 2, and the appropriateness for HTA is provided
in Table 3. We provide an overview of methods in each
group in the following subsections. We do not further
describe the ITT analysis, since it does not attempt to
adjust for nonadherence.
Simple Methods
Per-protocol analysis. The standard per-protocol (PP)
analysis strategy attempts to estimate the treatment effect
among adherent patients by excluding protocol noncom-
pliers.45 PP can deal with random (nonselective) types of
nonadherence (initiation, implementation, persistence).
The main concern is that excluding some patients from
the analysis may undermine the prognostic balance gen-
erated by the randomization, which may introduce selec-
tion bias. This is likely to be the case if nonadherence is
not random (i.e., if nonadherence is influenced by other
patient characteristics and prognostic factors).55 Even if
prognostic factors that are associated with nonadherence
are correctly identified, PP analysis will introduce bias in
the presence of time-dependent confounding.
As-treated analysis. The as-treated (AT) method attempts
to adjust for the random initiation type of nonadherence.
AT estimates the average causal effect (ACE) among
patients who actually received the treatment compared to
those who did not receive the treatment, assuming they are
similar regardless of randomization.34 The main problem
with this approach is that the group who actually received
the treatment is unlikely to be comparable to the group
who did not, making this approach prone to selection
bias.56 AT analysis is less commonly used in practice com-
pared with ITT and PP conventional methods.
Principal Stratification Methods
Cox proportional hazards model with partial likelihood
estimator. The Cox proportional hazards (CPH) model
with partial likelihood estimator (PLE) is a method for
estimating the treatment effect adjusted for initiation
nonadherence at baseline while respecting the randomi-
zation.41 This is a semiparametric model whereby the
treatment effect on the distributions of failure times is
the parametric part. In the basic model, an individual
with covariates (k, z0, z) will have a hazard function pre-
sented in equation (1).
exp gT z0 +bz+ gkð Þl tð Þ; ð1Þ
where gT is the treatment effect in compliers (CACE esti-
mand) expressed in terms of the hazard at time t for a
cumulative hazard function Lk(t) (this is only observable
for the compliers class), gk is the adherence class of the
kth individual, z0 is a vector of baseline covariates, and z
is a set of time-dependent covariates. The standard
method assumes that covariates are independent of non-
adherence. The method can be used to adjust for nonad-
herence in situations where nonadherence is dependent
on baseline covariates, but this approach requires a more
complex estimator.41 The key limitation of this method
is the difficulty of modeling time-varying treatments and
other types of nonadherence beyond initiation.
Markov compliance class model in a 3-stage method. The
Markov compliance class (MCC) model can accommo-
date both initiation and time-varying nonadherence
(implementation) in the context of longitudinal studies
where patients are randomized at baseline and randomi-
zation is maintained over time.42 The concept of this
method is based on specifying 2 possible adherence
classes that are applied at specified time points; for exam-
ple, 5 time points results in a total of 32 (25) adherence
patterns. A stratification strategy can then be used to
stratify adherence patterns into superclasses (low com-
pliers, decreasing compliers, and high compliers). This
can be used to estimate the CACE estimand among the
compliers superclass. Model (2) can then be used to
account for the relationship between adherence and sur-
vival time at time t.
h tjUi = kð Þ= h0 tð Þexp bkI Ui = kð Þð Þ; ð2Þ
where bk for one of the adherence superclasses is
assumed 0 for identification (reference superclass) and Ui
is individual i’s adherence superclass for a k number of
superclasses.42 As a limitation, the method cannot deal
with time-dependent confounding.
Weighted per-protocol analysis with expectation-
maximization estimator. The weighted per-protocol
(Wtd PP) method estimates the CACE by focusing on
the ambivalent (compliers) class. The method attempts
to deal with treatment initiation over time with 2 main
features: 1) proposing a Wtd PP estimator by using
time-varying weights that are subject specific (depend
on baseline and time-dependent covariates) in a survival
model and 2) proposing an expectation-maximization
algorithm to maximize the full likelihood (FL) and
PLEs.47 The method was developed to adjust for
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Table 2 Estimands, Causal Interpretation of Estimates, and Key Assumptions for Nonadherence Adjustment Methods
Method Estimanda Estimand Attribues Causal Interpretation of the Estimate Key Assumptions
ITT The effect of treatment
assignment (not the effect
of treatment itself)
Entire study population;
ignoring events such as
nonadherence and dropout
The average causal effect of treatment
assignment on the survival outcome
in a particular study (regardless of
adherence, dropout, etc.)
The randomization assumption
(i.e., group membership is
randomly assigned), which
implies that groups are
comparable or exchangeable
PP The effect of following the
study protocol
Subpopulation of the protocol




The average causal effect of treatment
on the survival outcome in
individuals who adhered to the
protocol in terms of eligibility,
adherence, outcome assessment, etc.
The groups of patients who
adhered to the protocol in each
arm are comparable after
covariate adjustment.
AT The effect of treatment
actually received
Subpopulation of patients who
initiated treatment, with
patients who switched
treatment analyzed with the
group they switched to
regardless of randomization
The average causal effect of treatment
on the survival outcome among
individuals who actually received the
treatment in the experimental group
(including control group patients
who switched onto the experimental
treatment) compared to those who
actually received the standard
treatment (or those who actually did
not receive the treatment in placebo-
controlled trials) regardless of
treatment assignment
The group of patients who
received the treatment is
comparable to those who did
not, regardless of their
treatment assignment.
CPH with PLE CACE Subpopulation who adhered
to the protocol, excluding
patients who did not adhere
to the protocol in each arm
of the study
The average treatment effect on the
survival outcome in the complier
subpopulation (patients who
adhered to the protocol)
Covariates included in the model
are independent of adherence.
MCC CACE As above As above The Markov assumption
Time-varying adherence
depends on the history of
adherence
Latent and ignorable missing
data mechanism




C-PROPHET CACE As above As above The exclusion restriction
assumption
IV CACE As above As above The exclusion restriction
assumption
Randomization has no effect on








Method Estimanda Estimand Attribues Causal Interpretation of the Estimate Key Assumptions
MSMs with
IPCW/IPTW
The effect of treatment had
everyone remained
adherent to the protocol
Entire study population; had
everybody adhered to the
protocol with perfect
adherence to the prescribed
dosing regimen or had
everybody adhered to the
protocol at an alternative
level of adherence to the
prescribed dosing regimen
than what was observed in
the trial (e.g., real-world
adherence level)
The average causal effect of treatment
that would have been observed if
everybody adhered to the protocol.
MSMs estimate the average
treatment effect in the entire
population, but the causal effect in a
subset of the population (defined by
a combination of variables L) can
also be estimated. The IPCW
estimand can also be interpreted as a
comparison of the potential
(counterfactual) outcomes under
different levels of adherence in the





The effect of treatment had
everyone remained
adherent to the protocol
As above The average treatment effect that
would have been observed if
everybody adhered to the protocol
(or remained at a particular
adherence level such as real-world
adherence level). SNFTMs can be
used to estimate the average causal
effect in a subset of the population
defined by a combination of factors
(L), e.g., men, patients aged .60
years
No unmeasured confounders
Survival times and treatment-free
survival times are proportional
by an unknown factor that
depends on the exposure.
RPSFTMs with
G-estimation
The effect of treatment had
everyone remained
adherent to the protocol
As above The average treatment effect that
would have been observed if
everybody adhered to the protocol
compared to none treated.
The randomization assumption
The common treatment effect
assumption
Survival times and treatment-free
survival times are proportional
by an unknown factor that
depends on the exposure.
PKPD method The effect of following a
particular adherence
pattern in the study
population
Entire study population; given
a particular pattern of
adherence to the prescribed
dosing regimen
The average causal effect of treatment





AT, as treated; CACE, complier average causal effect; CPH, Cox proportional hazards; C-PROPHET, Complier PROPortional Hazards Effect of Treatment; IPCW, inverse
probability of censoring weighting; IPTW, inverse probability of treatment weighting; ITT, intention to treat; IV, instrumental variable; MCC, Markov compliance class; MSMs,
marginal structural models; PKPD, pharmacokinetics and pharmacodynamics; PLE, partial likelihood estimator; PP, per protocol; RPSFTMs, rank-preserving structural failure
time models; SNFTMs, structural nested failure time models; Wtd PP, weighted per protocol.
aThe estimand is the parameter of interest defined using 4 attributes: 1) the population, 2) the outcome variable or endpoint, 3) the specification of how to deal with intercurrent
events (e.g., include compliers only), and 4) the population-level summary of the outcome variable. The description of the estimand in this table is focused on 2 attributes (the
population and specification of how to deal with intercurrent events), as the other 2 attributes (the outcome variable and the population-level summary of the outcome variable) are




Table 3 Appropriateness of Estimand for the HTA Context, Types of Nonadherence, Possibility to Account for Real-World Adherence Levels, and Suitability of





Type of Nonadherence That Can Be
















ITT Yes None None No No The estimand is marginalized to the
entire population.
Cannot estimate counterfactual
estimands (i.e., treatment effectiveness





Random No No The estimand is not marginalized to the
entire population.
Excluding the protocol noncompliers
may break the randomization balance,
leading to selection bias if protocol
noncompliance is related to
underlying prognosis.
AT No Initiation Random No No Does not respect the randomization




CPH with PLE No Initiation Random,
explainable
nonrandom
No No The CACE estimand used by all 5
methods is not marginalized to the
entire population.
The compliers class is a latent group of
patients that is not identifiable at
baseline, making it difficult for
policymakers to make resource
allocation decisions based on CACE
estimand.
IV can estimate effectiveness given real-





Wtd PP No Initiation Explainable
nonrandom
No No














Type of Nonadherence That Can Be





















Yes Yes Effectiveness estimates are marginalized
to entire study population.
Can be used to account for real-world
adherence levels.
RPSFTM only estimates the ‘‘all
treated’’ v. ‘‘nontreated’’ estimand,
making it applicable to adjust for













Yes Yes The estimand is marginalized to the
entire population.
Can estimate effectiveness given
different adherence patterns.
AT, as treated; CACE, complier average causal effect; CPH, Cox proportional hazards; C-PROPHET, Complier PROPortional Hazards Effect of Treatment; HTA, health
technology assessment; IPCW, inverse probability of censoring weighting; IPTW, inverse probability of treatment weighting; ITT, intention to treat; IV, instrumental variable; MCC,
Markov compliance class; MSMs, marginal structural models; PKPD, pharmacokinetics and pharmacodynamics; PLE, partial likelihood estimator; PP, per protocol; RPSFTMs,
rank-preserving structural failure time models; SNFTMs, structural nested failure time models; Wtd PP, weighted per protocol.
aIn the HTA context, the estimand of interest includes the entire study population, and this should be identifiable at baseline for resource allocation decision making.
bThis column specifies the type of nonadherence that each adjustment method is capable of dealing with in terms of random (nonselective) nonadherence, explainable nonrandom
(selective) nonadherence (i.e., nonadherence explainable by observed covariates), or no-random (selective) nonadherence.





time-dependent confounders, which are associated with
nonadherence. The partial likelihood estimator used by
this model is similar to that used in the CPH with PLE
approach (model (1)). Details of the FL estimator are
reported in Li and Gray.47
Compliers PROPortional Hazards Effect of Treatment. The
Compliers PROPortional Hazards Effect of Treatment (C-
PROPHET) identifies adherent patients (initiation at
baseline) and estimates the treatment effect in this group,
adjusting for baseline covariates.39 C-PROPHET is a semi-
parametric model with the parametric side being the effect
of the exposure on the survival times distribution.39 If indi-
vidual patients who actually adhered to the protocol can be
predicted at baseline in the intervention and control arms
of an RCT, then one could fit a PH model for this study
subpopulation to estimate the treatment effect.
The C-PROPHET model assumes that the hazard of
survival time (Ti) is as provided in equation (3).
39
l tjZi= 1,E1i = 1ð Þ= l tjZi = 0,E1i = 1ð Þexp c0ð Þ; ð3Þ
where Zi is the randomization variable for individual i
(Zi = 1 for the intervention group, Zi = 0 for the control
group) and E1i represents the principal stratum at the
treatment initiation stage. The parameter c0 denotes the
causal proportional hazards effect in the subpopulation
of compliers. This is the parameter of interest that is
called C-PROPHET.39 In terms of limitations, the
method cannot be used to adjust for time-dependent
nonadherence.
Instrumental variable method. The instrumental variable
(IV) method can be used for adjusting for all types of
nonadherence using a binary adherence variable. The
method relies on the exclusion restriction assumption;
that is, the IV affects the survival outcome only through
its effects on the exposure. Three variants of the IV
approach were identified: 1) IV with likelihood estima-
tor,32 2) IV with plug-in nonparametric empirical maxi-
mum likelihood estimator (PNEMLE),43 and 3)
transformation promotion time cure model with maxi-
mum likelihood estimator (MLE).48
The IV with likelihood estimator works by classifying
individuals in the trial population into 4 groups (similar
to the classification used by MCC method). The estima-
tor should be used to calculate the probability of having
the case-specific event of interest at time t for each latent
adherence class. Treatment effect in terms of hazard ratio
(HR) can then be computed. This method was further
applied to estimate adherence-adjusted cost-effectiveness
using RCT data.32
The PNEMLE approach assumes the following sur-
vival functions for compliers in the intervention group
(equation (4)), denoted as Sc1(V), and control group
(equation (5)), denoted as Sc0(V), while never-takers
have similar survival function in both groups, denoted as
Snt(V).
ST jR= 1 Vð Þ=pcSc1 Vð Þ+ 1 pcð ÞSnt Vð Þ; ð4Þ
ST jR= 0 Vð Þ=pcSc0 Vð Þ+ 1 pcð ÞSnt Vð Þ; ð5Þ
where pc is the fraction of compliers in the intervention
group.
The IV extension using transformation promotion
time cure model is a semiparametric model for estimat-
ing CACE and complier effect on survival probability
(CESP) estimands. Further details of this extension are
reported in Gao and Zheng.48 By using an IV approach,
the analyst can deal with time-dependent confounding.
The main drawback of this method is finding an instru-
mental variable that meets all the criteria of a valid IV15;
an inadequate IV can lead to an imprecise and/or biased
estimate.
G-Methods
Marginal structural models with inverse probability of
censoring weighting/inverse probability of treatment
weighting. This method can be used to adjust for all
types of nonadherence by censoring individuals at the
first time they become nonadherent and then use inverse
probability of censoring weighting (IPCW) for estimat-
ing the ACE of treatment using marginal structural mod-
els (MSMs).22 The IPCW can be used to obtain a valid
treatment effect by adjusting for baseline and time-
dependent confounders. IPCW makes the ‘‘no unmea-
sured confounding’’ assumption, that is, the assumption
of explainable nonrandom nonadherence by measured
time-dependent confounders.13,22 Stabilized weights are
used because unstabilized weights can be inefficient. In
practice, the analyst should construct stabilized weights
(ŵstabit ) for each individual i in time interval t by multiply-
ing all the probabilities of remaining uncensored (adher-
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where p̂ik is the predicted probability of nonadherence in
time interval k given the randomization group and
adjusting for baseline and time-dependent covariates,
and p̂0ik is the probability of nonadherence given the ran-
domization group and adjusting for baseline covariates
only. A pseudo-population should be created using the
IPCW, and then any survival analysis (e.g., a Cox partial
likelihood estimator) can be applied for estimating
adherence-adjusted effectiveness. The main limitation of
IPCW is the assumption of no unmeasured confounders,
which cannot be proven empirically.
As an alternative approach to IPCW, one could allow
individuals to become adherent again following a period
of nonadherence—this can be modeled using the inverse
probability of treatment weighting (IPTW) approach.35
The key feature of this method is that it allows for model-
ing longitudinal adherence patterns where patients follow
erratic adherence behaviors in implementing the pre-
scribed dosing regimen (i.e., on/off adherence patterns).
Structural nested failure time models with G-estimation. The
structural nested failure time models (SNFTMs) can be
applied to adjust for all types of nonadherence by con-
trolling for time-dependent confounding using the G-
estimation technique.31 The model relates the individu-
al’s observed survival time and treatment history to the
counterfactual outcome. In the SNFTM framework, the
no unmeasured confounding assumption implies that the
potential outcome does not add to the prediction model
for treatment initiation, conditional on other covariates
included in the model. To formally explain the G-estima-
tion procedure, let us assume the treatment effect model
in equation (7).57 We fit a logistic regression model to
obtain the coefficients in equation (8).
Y t;Xc tð Þgiven At, Ltð Þ; ð7Þ
P A tð Þ½ =b0 tð Þ+b1A t  1ð Þ+b2L tð Þ+b3Xc; ð8Þ
where Y t is the observed survival time, ;means has the
same distribution as, Xc tð Þ is the counterfactual outcome,
At is the past treatment, Lt is the history of covariates,
and P A tð Þ½  is the probability of initiating the treatment
at time t.
G-estimation is used to search for c value, which adds
the least to the prediction model (i.e., treatment initia-
tion is independent of counterfactual outcomes). This
means we search for a value of ĉ that results in a Xc term
having a coefficient b3 = 0 in model (8). That value of c
provides the best estimates of counterfactual survival
times adjusted for nonadherence. The main limitation of
SNFTMs is the potential biases related to the no unmea-
sured confounding assumption, which cannot be for-
mally tested.
Rank-preserving structural failure time models with G-
estimation. The rank-preserving structural failure time
model (RPSFTM) is a semiparametric model for adjust-
ing for initiation nonadherence using the randomization
factor, observed survival time, and treatment history.36
The method relies on the ‘‘common treatment effect’’
assumption (equal treatment effect regardless of when
the treatment was initiated but relative to the time for
which the treatment was received). It also relies upon the
randomization of the trial, meaning that counterfactual
survival times are equal between groups.
A simple RPSFTM (equation (9)) can be constructed






where Zi is the randomization variable, Ai is a binary
adherence variable that equals 1 when a patient initiated
the treatment and 0 otherwise, Ti is the observed survival
time, and the factor exp cð Þ is the causal effect (the value
by which survival time is shrunk or expanded as an effect
of the treatment). At the ‘‘true’’ value of the parameter c
(which we can find using G-estimation), the counterfac-
tual survival between randomized groups will be equal,
and that value of c would be the point estimate of the
treatment effect.
RPSFTM allows us to deal with time-dependent
initiation issues and can deal with time-dependent con-
founding. The original RPSFTM was extended to incor-
porate baseline covariates to improve the precision of
estimators37,38 and uses recensoring to allow the method
to deal with potentially informative censoring in the
counterfactual data set.33,40 As limitations, the RPSFTM
can only be used for adjusting for the initiation type of
nonadherence, and it relies on the common treatment
effect assumption, which is difficult to test.
Pharmacometrics-Based Methods
Pharmacokinetics and pharmacodynamics–based method.
The Pharmacokinetics and pharmacodynamics (PKPD)–
based methods model all types of nonadherence for esti-
mating treatment effectiveness. PKPD-based methods
require model development and fitting using appropriate
data, typically collected during each phase of clinical
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drug development, as well as simulation based on differ-
ent patterns of adherence, dosing schedules, and patient
characteristics where covariate effects are relevant. The
pharmacodynamic endpoint may be of direct relevance
(e.g., anticoagulant international normalized ratio [INR])
or may require extrapolation to estimate the link between
the PKPD parameter and the outcome of interest (e.g.,
risk of cardiovascular events) using evidence from the liter-
ature.44,58 PKPD makes the exclusion restriction assump-
tion, that is, randomization affects the outcome only
through the exposure treatment.
The PKPD method has been extended for modeling
varying nonadherence and estimating adherence-adjusted
cost-effectiveness of treatments.44,49 The main limitation of
this method is its reliance on an accurate model specifica-
tion and PKPD data, which might not be routinely avail-
able in RCTs or observational studies across disease areas.
Appropriateness of Nonadherence Adjustment
Methods to the HTA Context
The results based on the criteria applied for assessing
appropriateness (suitability of the estimand, type of non-
adherence, and possibility to account for real-world non-
adherence levels) for each of the identified adjustment
methods is provided in Table 3. Five methods (ITT,
MSMs, SNFTMs, RPSFTMs, and PKPD) generate the
estimand that is appropriate for HTA (covering the
entire study population), with only 3 of these being capa-
ble of accounting for all types of nonadherence (MSMs,
SNFTMs, and PKPD). Five methods are thought to be
capable of reestimating effectiveness for real-world levels
of nonadherence. When looking across all 3 facets of
estimating effectiveness for HTA, g-methods and PKPD
appear to be more appropriate.
The main differences between the 4 classes of methods
are the estimands, assumptions, and the types of nonad-
herence that each method is capable of dealing with.
Simple methods are only valid in the presence of random
(nonselective) nonadherence. Principal stratification
methods are capable of adjusting for some types of non-
adherence, but their estimands seem inappropriate for
the HTA context based on the criteria we set out in the
Methods section. Both g-methods and PKPD can deal
with real-world nonadherence, and their estimands are
appropriate for HTA. G-methods are similar in terms of
their capability for adjusting effectiveness estimates for
counterfactual nonadherence levels. However, PKPD is
a unique method that uses a different approach com-
pared to g-methods.
In practice, the analyst could apply g-methods to indi-
vidual patient-level data from an RCT to reestimate
treatment effectiveness (adjusted for nonadherence) for
populating cost-effectiveness models. Real-world adher-
ence levels could be estimated from registry data or
observational studies. All g-methods could be applied
using standard software (e.g., SAS, Stata, or R).12,59–61
While g-methods could be applied to real RCT data sets,
the PKPD approach relies on simulating an RCT data
set based on a specified pattern of nonadherence (e.g.,
real-world adherence) and then uses the simulated data
for generating the adjusted estimates. This would require
data (including PKPD data) collected at different phases
of clinical drug development. The PKPD method can be
applied using a specialist software (e.g., NONMEM) or
standard software (e.g., R) for simulating the data set.62
Discussion
A total of 12 methods for adjusting for nonadherence in
the context of time-to-event outcomes were identified
and briefly described in this article. The proposed taxon-
omy classifies adjustment methods into 4 groups: 1) sim-
ple methods, 2) principal stratification methods, 3)
g-methods, and 4) pharmacometrics-based methods.
Each method makes specific assumptions and has associ-
ated limitations, and many of these assumptions are non-
testable. Identification and collection of baseline and
time-dependent confounders were identified as crucial
for adjusting for nonadherence.
The purpose of adjustment was highlighted as a funda-
mentally important issue as estimands differ between the
methods, as do the practicalities of using the method to
reestimate effectiveness for alternative levels of adherence.
G-methods and PKPD appear more appropriate for
adjusting effectiveness estimates given real-world adher-
ence levels and the likely existence of time-dependent con-
founding in RCT data sets. Simple methods and principal
stratification methods cannot reestimate effectiveness
based on alternative, suboptimal adherence levels. The
Wtd PP method uses weights similar to IPCW, but the
estimand is restricted to the complier subpopulation.
Many potentially relevant papers with a focus on
cost-effectiveness aspects were excluded as these did not
provide a methodological contribution. This gap in the
methodological literature on CEA for modeling the link
between nonadherence and treatment effectiveness is
consistent with findings from other studies.8,63 A previ-
ous review by Hughes et al.27 reported 5 methods for
adjusting cost-effectiveness for nonadherence, which was
focused on pharmacoeconomic models rather than the
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impact of nonadherence on effectiveness. In that review,
the PKPD approach is the only method relevant to our
review, with the other methods being health-economic
models (decision tree, Markov, discrete-event simulation)
for incorporating adherence-adjusted treatment effects in
economic evaluations.
Many of the methods identified by our review have
been described and compared (mostly in pairwise com-
parisons) in the methodological literature.13,14,34,64,65
Mostazir et al.66 published a review of methods for han-
dling nonadherence to intervention protocols in RCTs that
identified some of the methods; however, their review
missed several relevant methods due to the restricted
search strategy used. The limitations of simple methods in
adjusting for nonadherence are consistently reported in the
methodological literature.33,34,39,45,56,64,67 It has been noted
previously that principal stratification methods require a
binary adherence variable (e.g., compliers/noncompliers),
which may be problematic as a threshold is required, and
this is often arbitrarily decided (e.g., 80% adherence
level).68 This may also be an issue for g-methods and
PKPD methods, where, in adjusting for nonadherence, we
first need to define what constitutes ‘‘adherence.’’ This
review has identified which nonadherence adjustment
methods are likely to be useful in an HTA context.
However, the remaining methods all have limitations, and
their performance in relevant scenarios is unknown.
This review has used novel iterative search techniques
and followed international guidelines16–18 but has limita-
tions. First, a higher number of papers were excluded at
the title screening stage because the paper’s title was not
relevant. Second, we excluded non-peer-reviewed reports
and other gray literature. While these two limitations
might be an issue, the final list of included papers was
checked by 2 experts, and we are confident that no
important relevant method was missed. Third, minor var-
iants of methods extensions are not included (e.g., pro-
posing alternative censoring mechanisms for IPCW),69
which is inevitably a subjective decision. These decisions
were based on discussions among the authors. Finally,
the review does not assess the performance of the alterna-
tive methods; therefore, further research (well-conducted
simulation studies) is warranted to provide recommenda-
tions for application in the HTA context.
In conclusion, economic evaluations frequently ignore
the adjustment of treatment effectiveness for patient non-
adherence, which carries the risk of producing misleading
cost-effectiveness evidence if adherence levels in the real
world differ from trials. A range of statistical methods is
available for adjusting estimates of treatment effective-
ness in the presence of patient nonadherence, although g-
methods and PKPD appear to be more promising to
account for real-world adherence levels in HTA. Further
research is warranted to assess the performance of these
methods.
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